Chris Wilkinson1, Jianhua Wu2,3, Samuel D Searle4,5, Oliver Todd3,6,7, Marlous Hall2,3, Vijay Kunadian8,9, Andrew Clegg6,7, Kenneth Rockwood4,5, Chris P Gale2,3,10. 1. Population Health Sciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, NE2 4HH, UK. Chris.Wilkinson@newcastle.ac.uk. 2. Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK. 3. Leeds Institute for Data Analytics, University of Leeds, Leeds, UK. 4. MRC Unit for Lifelong Health and Ageing, University College London, London, UK. 5. Geriatric Medicine, Dalhousie University, Halifax, Nova Scotia, Canada. 6. Academic Unit for Ageing and Stroke Research, University of Leeds, Leeds, UK. 7. Bradford Teaching Hospitals NHS Foundation Trust, Bradford, UK. 8. Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK. 9. Cardiothoracic Centre, Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, UK. 10. Department of Cardiology, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
Abstract
BACKGROUND: Atrial fibrillation (AF) is common in older people with frailty and is associated with an increased risk of stroke and systemic embolism. Whilst oral anticoagulation is associated with a reduction in this risk, there is a lack of data on the safety and efficacy of direct oral anticoagulants (DOACs) in people with frailty. This study aims to report clinical outcomes of patients with AF in the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-TIMI 48) trial by frailty status. METHODS: Post hoc analysis of 20,867 participants in the ENGAGE AF-TIMI 48 trial, representing 98.8% of those randomised. This double-blinded double-dummy trial compared two once-daily regimens of edoxaban (a DOAC) with warfarin. Participants were categorised as fit, living with pre-frailty, mild-moderate, or severe frailty according to a standardised index, based upon the cumulative deficit model. The primary efficacy endpoint was stroke or systemic embolism and the safety endpoint was major bleeding. RESULTS: A fifth (19.6%) of the study population had frailty (fit: n = 4459, pre-frailty: n = 12,326, mild-moderate frailty: n = 3722, severe frailty: n = 360). On average over the follow-up period, the risk of stroke or systemic embolism increased by 37% (adjusted HR 1.37, 95% CI 1.19-1.58) and major bleeding by 42% (adjusted HR 1.42, 1.27-1.59) for each 0.1 increase in the frailty index (four additional health deficits). Edoxaban was associated with similar efficacy to warfarin in every frailty category, and a lower risk of bleeding than warfarin in all but those living with severe frailty. CONCLUSIONS: Edoxaban was similarly efficacious to warfarin across the frailty spectrum and was associated with lower rates of bleeding except in those with severe frailty. Overall, with increasing frailty, there was an increase in stroke and bleeding risk. There is a need for high-quality, frailty-specific population randomised control trials to guide therapy in this vulnerable population. TRIAL REGISTRATION: ClinicalTrials.gov NCT00781391 . First registered on 28 October 2008.
BACKGROUND: Atrial fibrillation (AF) is common in older people with frailty and is associated with an increased risk of stroke and systemic embolism. Whilst oral anticoagulation is associated with a reduction in this risk, there is a lack of data on the safety and efficacy of direct oral anticoagulants (DOACs) in people with frailty. This study aims to report clinical outcomes of patients with AF in the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-TIMI 48) trial by frailty status. METHODS: Post hoc analysis of 20,867 participants in the ENGAGE AF-TIMI 48 trial, representing 98.8% of those randomised. This double-blinded double-dummy trial compared two once-daily regimens of edoxaban (a DOAC) with warfarin. Participants were categorised as fit, living with pre-frailty, mild-moderate, or severe frailty according to a standardised index, based upon the cumulative deficit model. The primary efficacy endpoint was stroke or systemic embolism and the safety endpoint was major bleeding. RESULTS: A fifth (19.6%) of the study population had frailty (fit: n = 4459, pre-frailty: n = 12,326, mild-moderate frailty: n = 3722, severe frailty: n = 360). On average over the follow-up period, the risk of stroke or systemic embolism increased by 37% (adjusted HR 1.37, 95% CI 1.19-1.58) and major bleeding by 42% (adjusted HR 1.42, 1.27-1.59) for each 0.1 increase in the frailty index (four additional health deficits). Edoxaban was associated with similar efficacy to warfarin in every frailty category, and a lower risk of bleeding than warfarin in all but those living with severe frailty. CONCLUSIONS: Edoxaban was similarly efficacious to warfarin across the frailty spectrum and was associated with lower rates of bleeding except in those with severe frailty. Overall, with increasing frailty, there was an increase in stroke and bleeding risk. There is a need for high-quality, frailty-specific population randomised control trials to guide therapy in this vulnerable population. TRIAL REGISTRATION: ClinicalTrials.gov NCT00781391 . First registered on 28 October 2008.
Authors: Angelica P Herrera; Shedra Amy Snipes; Denae W King; Isabel Torres-Vigil; Daniel S Goldberg; Armin D Weinberg Journal: Am J Public Health Date: 2010-02-10 Impact factor: 9.308
Authors: Adam Timmis; Nick Townsend; Chris P Gale; Aleksandra Torbica; Maddalena Lettino; Steffen E Petersen; Elias A Mossialos; Aldo P Maggioni; Dzianis Kazakiewicz; Heidi T May; Delphine De Smedt; Marcus Flather; Liesl Zuhlke; John F Beltrame; Radu Huculeci; Luigi Tavazzi; Gerhard Hindricks; Jeroen Bax; Barbara Casadei; Stephan Achenbach; Lucy Wright; Panos Vardas Journal: Eur Heart J Date: 2020-01-01 Impact factor: 29.983
Authors: Campbell Cowan; Richard Healicon; Ian Robson; W Robert Long; James Barrett; Matthew Fay; Keith Tyndall; Chris P Gale Journal: Heart Date: 2013-02-07 Impact factor: 5.994
Authors: Andrew Clegg; Chris Bates; John Young; Ronan Ryan; Linda Nichols; Elizabeth Ann Teale; Mohammed A Mohammed; John Parry; Tom Marshall Journal: Age Ageing Date: 2016-03-03 Impact factor: 10.668
Authors: Jordan B Strom; Jiaman Xu; Ariela R Orkaby; Changyu Shen; Yang Song; Brian R Charest; Dae H Kim; David J Cohen; Daniel B Kramer; John A Spertus; Robert E Gerszten; Robert W Yeh Journal: Circ Cardiovasc Qual Outcomes Date: 2021-11-15
Authors: Igor Diemberger; Stefano Fumagalli; Anna Maria Mazzone; Ameet Bakhai; Paul Egbert Reimitz; Ladislav Pecen; Marius Constantin Manu; José Antonio Gordillo de Souza; Paulus Kirchhof; Raffaele De Caterina Journal: Europace Date: 2022-10-13 Impact factor: 5.486
Authors: Marta Wleklik; Quin Denfeld; Magdalena Lisiak; Michał Czapla; Marta Kałużna-Oleksy; Izabella Uchmanowicz Journal: Int J Environ Res Public Health Date: 2022-02-16 Impact factor: 3.390
Authors: Chris Wilkinson; Jianhua Wu; Andrew Clegg; Ramesh Nadarajah; Kenneth Rockwood; Oliver Todd; Chris P Gale Journal: Europace Date: 2022-07-21 Impact factor: 5.486
Authors: Christopher Hohmann; Magnus Lutz; Sheila Vignali; Kathrin Borchert; Karolin Seidel; Sebastian Braun; Stephan Baldus; Michael Näbauer Journal: Thromb J Date: 2022-07-04
Authors: Marco Proietti; Marina Camera; Maurizio Gallieni; Luigi Gianturco; Antonio Gidaro; Carlo Piemontese; Giuseppe Pizzetti; Franco Redaelli; Barbara Scimeca; Carlo Sebastiano Tadeo; Matteo Cesari; Giuseppe Bellelli; Laura Adelaide Dalla Vecchia Journal: J Pers Med Date: 2022-03-15